November 2020

• Structural basis of SARS-CoV-2 polymerase inhibition by Favipiravir.
• *Research Tool Identification of SARS-CoV-2 Inhibitors using Lung and Colonic Organoids.
• *Research Tool SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging.
• *Research Tool Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase.

October 2020

• *Research Tool Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.

September 2020

• Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
• Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.

August 2020

• Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase.
• In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.

July 2020

• Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.
• Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
• Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
• Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.
• Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
• Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).
• Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.
• Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.

June 2020

• Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.
• Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
• Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.

May 2020

• Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
• Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network.
• Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
• Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
• Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.
• Current targeted therapeutics against COVID-19: based on first-line experience in china.
• A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

April 2020

• Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
• Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection.
• Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.

December 2020

• Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

November 2020

• Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.
• Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
• Aprotinin Inhibits SARS-CoV-2 Replication.
• Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium.
• Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.

October 2020

• Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
• Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
• Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
• Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
• Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
• Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.

September 2020

• De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
• Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
• Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and coronaviruses by depleting membrane cholesterol.
• Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
• Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.

August 2020

• De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
• The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
• SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2.
• Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
• Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
• Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
• A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.
• Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main Protease of SARS-CoV-2.

July 2020

• Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
• Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
• Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication.
• Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
• The Effect Of Famotidine On SARS-CoV-2 Proteases And Virus Replication.
• Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
• 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities.
• Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2.

June 2020

• The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
• Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.

May 2020

• Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
• Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
• Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
• Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design.
• An engineered stable mini-protein to plug SARS-Cov2 Spikes.

April 2020

• Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19.
• The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.
• Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis.
• The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.
• Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
• Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir Against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study.
• Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
• An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
• Compassionate Use of Remdesivir for Patients with Severe Covid-19.

December 2020

• Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.
• Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
• A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
• *Research Tool ACE2-Targeting Monoclonal Antibody As A "Pan" Coronavirus Blocker In Vitro and In A Mouse Model.
• Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
• Prevention of severe COVID-19 in the elderly by early high-titer plasma.

November 2020

• *NEW Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
• *NEW *Research Tool Rapid generation of potent antibodies by autonomous hypermutation in yeast.
• Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
• Highly potent bispecific sybodies neutralize SARS-CoV-2.
• *Research Tool Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
• SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
• *Research Tool A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies.
• Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.
• SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
• Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.
• Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein.

October 2020

• Extremely potent human monoclonal antibodies from convalescent Covid-19 patients.
• Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
• REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
• Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers.
• LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
• Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
• A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.
• *Research Tool Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.
• *Research Tool High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.
• Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.

September 2020

• A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.
• Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.
• Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
• Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.
• Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
• Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo.
• Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial).
• REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.

August 2020

• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
• Type I and Type III Interferon Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
• High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
• High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme.

July 2020

• Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization.
• Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
• Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
• Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike.
• Immune-mediated approaches against COVID-19.
• SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.
• Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.

June 2020

• Structural basis of a public antibody response to SARS-CoV-2.
• Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
• Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.
• Dissecting antibody-mediated protection against SARS-CoV-2.
• Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.
• Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
• SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
• Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
• CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients.
• Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.

May 2020

• Human neutralizing antibodies elicited by SARS-CoV-2 infection.
• A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.
• Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.
• Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.
• Early Safety Indicators of COVID-19 ConvalescentPlasma in 5,000 Patients.
• Potential antiviral options against SARS-CoV-2 infection.

April 2020

• Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors.
• Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.
• Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.
• Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
• A human monoclonal antibody blocking SARS-CoV-2 infection.
• A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.
• Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
• Fully human single-domain antibodies against SARS-CoV-2.

December 2020

• Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism.
• Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

November 2020

• Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
• Treatment of SARS-CoV-2 induced pneumonia with NAD+ in a mouse model.
• Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19.
• Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
• Evidence of protective role of Ultraviolet-B (UVB) radiation in reducing COVID-19 deaths.

August 2020

• Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience.
• An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation.

July 2020

• An Antioxidant Enzyme Therapeutic for COVID-19.
• Identification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.
• Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.

June 2020

• A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
• Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.
• Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.
• Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19.
• GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia.
• A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19.
• Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

May 2020

• Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism.
• Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
• Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.
• Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.

April 2020

• Stem cell-based therapy for coronavirus disease 2019.
• Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
• Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases.
• Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.
• Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19.
• Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.